Teva Pharma (TEVA) PT Lowered to $20 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $41.51 +0.83%
Rating Summary:
20 Buy, 19 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 16 | New: 33
Rating Summary:
20 Buy, 19 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 16 | New: 33
Join SI Premium – FREE
Wells Fargo analyst David Maris lowered the price target on Teva Pharma (NYSE: TEVA) to $20.00 (from $24.00) while maintaining a Market Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) PT Raised to $52 at Oppenheimer
- Descartes (DSGX) PT Raised to $90 at BMO Capital
- Invesco (IVZ) PT Raised to $36 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Wells Fargo, David MarisSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
